Start-Up Previews, February 2014
Executive Summary
This Month's Profile Group, Strategic Spin-Outs: Biotech Start-Ups Structure Their Progeny For Success, features profiles of Envisia Therapeutics, f-star Alpha, Onkaido Therapeutics, Seragon Pharmaceuticals, and True North Therapeutics. Plus these Start-Ups Across Health Care: Arecor, Gecko Biomedical, and MediValve.
You may also be interested in...
MediValve Ltd.
Complementing the rapidly growing transcatheter aortic valve implantation (TAVI) market is the acWire from MediValve Ltd., a guidewire specifically designed to accurately place and align medical devices in the cardiovascular system during the minimally invasive TAVI procedure.
Gecko Biomedical
Unlike competing surgical glues used for heart and vascular procedures that offer either strong adhesion or nontoxicity, or both, the liquid glue in development from Gecko Biomedical SAS offers the additional feature of being effective in a wet environment. Gecko’s product, derived from glycol and sebacic acid, is spread at room temperature on the wound in a viscous, pre-polymer state and adheres to tissue when activated by ultraviolet light.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.